Download our whitepaper,

Atopic Dermatitis Trials: Novel
Therapeutic Approaches

What's Inside:

  • EASI and IGA scoring systems for atopic dermatitis.
  • Pruritus assessment and itch severity measurement.
  • JAK inhibitor and biologic trial designs.
  • Pediatric considerations in atopic dermatitis research.
  • Topical vs systemic therapy trial strategies.
  • Sleep disturbance and quality of life endpoints.

Access your complimentary whitepaper today:






    Atopic Dermatitis

    Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin disease marked by itchy and inflamed skin. It is one of the most common skin diseases, especially among children, but it can persist into adulthood or start at an older age.

    Over the decades, research has evolved from viewing AD merely as an allergic condition to understanding its complex pathophysiology involving epidermal barrier dysfunction, immune dysregulation, and environmental and psychological factors.

    This shift has been pivotal in shaping current therapeutic strategies which aim to restore barrier function, reduce immune dysregulation, and manage environmental and lifestyle factors.

    iNGENū’s team of researchers and clinicians is dedicated to advancing atopic dermatitis research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by Atopic Dermatitis.

    Atopic Dermatitis affects approx

    15-20%

    of children and 1-3% of adults globally

    Around

    90%

    of cases are diagnosed before the age of 5

    The annual economic burden of atopic dermatitis in the U.S. is estimated to exceed

    $5b

    Our clinical team has over

    120

    years of combined clinical trial experience